Does the media favor NAMS or ELAN?

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 9 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.72 beat NewAmsterdam Pharma's score of 0.61 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NAMS or ABVX?

In the previous week, Abivax had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 13 mentions for Abivax and 10 mentions for NewAmsterdam Pharma. Abivax's average media sentiment score of 1.41 beat NewAmsterdam Pharma's score of 0.61 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NAMS or AXSM?

In the previous week, Axsome Therapeutics had 1 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 11 mentions for Axsome Therapeutics and 10 mentions for NewAmsterdam Pharma. Axsome Therapeutics' average media sentiment score of 0.77 beat NewAmsterdam Pharma's score of 0.61 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SMMT or NAMS?

In the previous week, Summit Therapeutics had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 13 mentions for Summit Therapeutics and 10 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.61 beat Summit Therapeutics' score of 0.35 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral NewAmsterdam Pharma 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARWR or NAMS?

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 21 mentions for Arrowhead Pharmaceuticals and 10 mentions for NewAmsterdam Pharma. Arrowhead Pharmaceuticals' average media sentiment score of 1.07 beat NewAmsterdam Pharma's score of 0.61 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NewAmsterdam Pharma (NAMS) Competitors

$27.79 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$27.76 -0.04 (-0.13%)

As of 07/31/2026 07:34 PM Eastern

Compare

NAMS vs. ELAN, ABVX, AXSM, SMMT, and ARWR

Should you buy NewAmsterdam Pharma stock or one of its competitors? MarketBeat compares NewAmsterdam Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NewAmsterdam Pharma include Elanco Animal Health (ELAN), Abivax (ABVX), Axsome Therapeutics (AXSM), Summit Therapeutics (SMMT), and Arrowhead Pharmaceuticals (ARWR).

How does NewAmsterdam Pharma compare to Elanco Animal Health?

NewAmsterdam Pharma (NASDAQ:NAMS) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 9 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.72 beat NewAmsterdam Pharma's score of 0.61 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NewAmsterdam Pharma presently has a consensus target price of $49.42, suggesting a potential upside of 77.82%. Elanco Animal Health has a consensus target price of $28.73, suggesting a potential upside of 8.72%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

NewAmsterdam Pharma has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	144.38	-$203.82M	-$1.79	N/A
Elanco Animal Health	$4.89B	2.70	-$232M	-$0.50	N/A

NewAmsterdam Pharma has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

Elanco Animal Health has a net margin of -4.95% compared to NewAmsterdam Pharma's net margin of -943.23%. Elanco Animal Health's return on equity of 7.42% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Elanco Animal Health	-4.95%	7.42%	3.66%

Summary

NewAmsterdam Pharma beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Abivax?

NewAmsterdam Pharma (NASDAQ:NAMS) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Abivax has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Abivax	N/A	-99.02%	-70.26%

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

NewAmsterdam Pharma has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	144.38	-$203.82M	-$1.79	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

In the previous week, Abivax had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 13 mentions for Abivax and 10 mentions for NewAmsterdam Pharma. Abivax's average media sentiment score of 1.41 beat NewAmsterdam Pharma's score of 0.61 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NewAmsterdam Pharma currently has a consensus target price of $49.42, suggesting a potential upside of 77.82%. Abivax has a consensus target price of $156.50, suggesting a potential upside of 25.28%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

NewAmsterdam Pharma has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, Abivax has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Summary

NewAmsterdam Pharma beats Abivax on 11 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

NewAmsterdam Pharma (NASDAQ:NAMS) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

In the previous week, Axsome Therapeutics had 1 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 11 mentions for Axsome Therapeutics and 10 mentions for NewAmsterdam Pharma. Axsome Therapeutics' average media sentiment score of 0.77 beat NewAmsterdam Pharma's score of 0.61 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has a net margin of -26.59% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Axsome Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. Axsome Therapeutics is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	144.38	-$203.82M	-$1.79	N/A
Axsome Therapeutics	$638.50M	17.57	-$183.17M	-$3.73	N/A

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NewAmsterdam Pharma currently has a consensus price target of $49.42, suggesting a potential upside of 77.82%. Axsome Therapeutics has a consensus price target of $261.29, suggesting a potential upside of 19.86%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe NewAmsterdam Pharma is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91

NewAmsterdam Pharma has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Summary

NewAmsterdam Pharma and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Summit Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Summit Therapeutics has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NewAmsterdam Pharma has higher revenue and earnings than Summit Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
NewAmsterdam Pharma	$22.50M	144.38	-$203.82M	-$1.79	N/A

In the previous week, Summit Therapeutics had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 13 mentions for Summit Therapeutics and 10 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.61 beat Summit Therapeutics' score of 0.35 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics currently has a consensus target price of $26.15, indicating a potential upside of 100.88%. NewAmsterdam Pharma has a consensus target price of $49.42, indicating a potential upside of 77.82%. Given Summit Therapeutics' higher probable upside, equities analysts plainly believe Summit Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Summary

NewAmsterdam Pharma beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.38	-$1.63M	-$2.15	N/A
NewAmsterdam Pharma	$22.50M	144.38	-$203.82M	-$1.79	N/A

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 21 mentions for Arrowhead Pharmaceuticals and 10 mentions for NewAmsterdam Pharma. Arrowhead Pharmaceuticals' average media sentiment score of 1.07 beat NewAmsterdam Pharma's score of 0.61 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Arrowhead Pharmaceuticals currently has a consensus target price of $96.92, indicating a potential upside of 14.49%. NewAmsterdam Pharma has a consensus target price of $49.42, indicating a potential upside of 77.82%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Summary

NewAmsterdam Pharma beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAMS vs. The Competition

Export

Metric	NewAmsterdam Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.25B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-15.53	7.38	282.30	24.66
Price / Sales	144.38	1,203.55	564.25	75.48
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	4.65	16.95	10.98	6.07
Net Income	-$203.82M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-8.04%	-1.81%	-0.60%	-0.44%
1 Month Performance	-20.21%	-8.43%	-5.19%	-4.81%
1 Year Performance	30.59%	48.41%	62.02%	18.61%

NewAmsterdam Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAMS NewAmsterdam Pharma	2.5763 of 5 stars	$27.79 flat	$49.42 +77.8%	+30.6%	$3.25B	$22.50M	N/A	4	Upcoming Earnings Gap Up
ELAN Elanco Animal Health	2.9495 of 5 stars	$25.46 +1.3%	$28.55 +12.1%	+91.5%	$12.71B	$4.72B	N/A	9,400	Positive News Upcoming Earnings Analyst Upgrade
ABVX Abivax	3.9321 of 5 stars	$134.09 +2.0%	$148.54 +10.8%	+73.6%	$11.69B	N/A	N/A	61	Positive News
AXSM Axsome Therapeutics	3.3115 of 5 stars	$236.95 +6.9%	$261.48 +10.4%	+111.6%	$11.41B	$708.24M	N/A	380	Upcoming Earnings Analyst Forecast Gap Up
SMMT Summit Therapeutics	3.4832 of 5 stars	$14.63 +8.4%	$26.97 +84.4%	-51.9%	$11.36B	N/A	N/A	110	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAMS) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. ELAN, ABVX, AXSM, SMMT, and ARWR

How does NewAmsterdam Pharma compare to Elanco Animal Health?

Summary

How does NewAmsterdam Pharma compare to Abivax?

Summary

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Summary

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Summary

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. ELAN, ABVX, AXSM, SMMT, and ARWR

How does NewAmsterdam Pharma compare to Elanco Animal Health?

Do insiders & institutionals have more ownership in NAMS or ELAN?

Does the media favor NAMS or ELAN?

Do analysts recommend NAMS or ELAN?

Which has higher earnings and valuation, NAMS or ELAN?

Which has more risk and volatility, NAMS or ELAN?

Is NAMS or ELAN more profitable?

Summary

How does NewAmsterdam Pharma compare to Abivax?

Is NAMS or ABVX more profitable?

Do institutionals & insiders have more ownership in NAMS or ABVX?

Which has preferable earnings and valuation, NAMS or ABVX?

Does the media favor NAMS or ABVX?

Do analysts prefer NAMS or ABVX?

Which has more volatility and risk, NAMS or ABVX?

Summary

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Does the media refer more to NAMS or AXSM?

Is NAMS or AXSM more profitable?

Which has better earnings and valuation, NAMS or AXSM?

Do insiders & institutionals hold more shares of NAMS or AXSM?

Do analysts recommend NAMS or AXSM?

Which has more risk and volatility, NAMS or AXSM?

Summary

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Is SMMT or NAMS more profitable?

Which has more risk & volatility, SMMT or NAMS?

Do insiders & institutionals have more ownership in SMMT or NAMS?

Which has better valuation & earnings, SMMT or NAMS?

Does the media prefer SMMT or NAMS?

Do analysts rate SMMT or NAMS?

Summary

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Do institutionals & insiders have more ownership in ARWR or NAMS?

Which has preferable valuation and earnings, ARWR or NAMS?

Does the media prefer ARWR or NAMS?

Which has more risk and volatility, ARWR or NAMS?

Is ARWR or NAMS more profitable?

Do analysts rate ARWR or NAMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools